Moreover, the phase III DESTINY-Breast03 (NCT03529110) trial reported (5.44 mg/kg three-weekly (q3w) and largely second-line) T-DXd-related ILD in 15.2% (n = 39) of previously treated HER2-positive metastatic BC patients. Here, ERBB2 is linked to interstitial lung disease.